Supplementary Table 2 from ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

2026 Open access

Read full text Summarise with VIRAT
Authors: Christopher T. Chen, Vishesh Khanna, Shivaani Kummar, Raghad M. Abdul-Karim, David Sommerhalder, Anthony W. Tolcher, Naoto Tada Ueno, Sarah Lindsey Davis, Douglas W. Orr, Erika Paige Hamilton, Manish R. Patel, Alexander I. Spira
+17 more Shekeab Jauhari, Vaia Florou, Maureen Duff, Rongda Xu, Jian Wang, Shravani R. Barkund, Haiying Zhou, Aleksandr Pankov, Wayne Kong, Nadine S. Jahchan, Erica L. Jackson, Jessica D. Sun, Melissa R. Junttila, Pratik S. Multani, Anneleen Daemen, Edna Chow Maneval, Pamela N. Münster
DOI: 10.1158/2767-9764.31762136
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Supplementary Table 2. TEAEs Occurring in at Least 15% of Dose Escalation Patients

Fields of Study & Subjects

Estrogen and related hormone effects Cancer Immunotherapy and Biomarkers Adrenal Hormones and Disorders

Publication details

Publication date
16 March 2026
Language
EN